Interpretation of genotypic HIV-1 resistance to darunavir and virological response: Validation of available systems and of a new score

Antiviral Therapy

Volumn 16, Issue 4, 2011, Pages 489-497

  De Luca, Andrea ^a,b   Di Giambenedetto, Simona ^a   Maserati, Renato ^c   Gianotti, Nicola ^d   Narciso, Pasquale ^e   Antinori, Andrea ^e   Di Perri, Giovanni ^f   Prosperi, Mattia C F ^a   Baldanti, Fausto ^c   Micheli, Valeria ^g   Zazzi, Maurizio ^h   Perno, Carlo F ⁱ   Santoro, Maria M ⁱ  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF SIENA   (Italy)

ⁱ UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; MARAVIROC; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPUTER SYSTEM; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRV 2009 SCORE; FOLLOW UP; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ITALY; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTION; PREDZISTA SCORE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REGA SCORE; SCORING SYSTEM; STANFORD HIVDB SCORE; TIBOTEC SCORE; TREATMENT OUTCOME; VALIDATION STUDY; VIRUS LOAD;

ALGORITHMS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PREDICTIVE VALUE OF TESTS; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 79959571411     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1799     Document Type: Article

References (28)

1. Zaccarelli M, Tozzi V, Lorenzini P, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19:1081-1089. (Pubitemid 40961149)
2. Di Giambenedetto S, Colafigli M, Pinnetti C, et al. Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. AIDS Res Hum Retroviruses 2008; 24:149-154. (Pubitemid 351282093)
3. Maggiolo F, Ripamonti D, Airoldi M, et al. Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort. HIV Clin Trials 2007; 8:9-18. (Pubitemid 46542905)
4. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 10 January 2011. Accessed 01 April 2011.) Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf
5. Clumeck N, Pozniak A, Raffi F, European Aids Clinical Society (EACS) Executive Committee. Guidelines for the clinical management and treatment of HIV-infected adults in Europe. Version 5.3. (Accessed 01 April 2011.) Available from http://www.europeanaidsclinicalsociety.org/guidelinespdf/1-Treatment-of- HIV-Infected-Adults.pdf
6. BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
7. HIV/AIDS Italian Expert Panel. Linee guida Italiane sull'utilizio degli antiretrovirali nelle persone con infezione da HIV. (Updated 15 July 2010. Accessed 12 April 2011.) Available from http://www.salute.gov.it/imgs/C-17- pubblicazioni-1301-allegato.pdf
8. Kovalevsky AY, Liu F, Leshchenko S, et al. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol 2006; 363:161-173. (Pubitemid 44437563)
9. Kovalevsky AY, Tie Y, Liu F, et al. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem 2006; 49:1379-1387. (Pubitemid 43271890)
10. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321. (Pubitemid 40734460)
11. Sayer JM, Liu F, Ishima R, Weber IT, Louis JM. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J Biol Chem 2008; 283:13459-13470.
12. Koh Y, Matsumi S, Das D, et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 2007; 282:28709-28720 (Pubitemid 47606016)
13. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of DRV-RTV at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. (Pubitemid 46541620)
14. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of DRV-RTV compared with that of lopinavir-RTV at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58. (Pubitemid 47023100)
15. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily DRV/RTV versus lopinavir/RTV in treatmentnaive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
16. Mills AM, Nelson M, Jayaweera D, et al. Once-daily DRV/RTV vs lopinavir/RTV in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679-1688.
17. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2008. Top HIV Med 2008; 16:138-145.
18. De Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of DRV: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24:379-388. (Pubitemid 351457745)
19. Pellegrin I, Wittkop L, Joubert LM, et al. Virological response to DRV/RTV-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther 2008; 13:271-279. (Pubitemid 351535378)
20. Descamps D, Lambert-Niclot S, Marcelin AG, et al. Mutations associated with virological response to DRV/RTV in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother 2009; 63:585-592.
21. Delaugerre C, Pavie J, Palmer P, et al. Pattern and impact of emerging resistance mutations in treatment experienced patients failing DRV-containing regimen. AIDS 2008; 22:1809-1813.
22. Stanford University HIV Drug Resistance Database. (Accessed 30 May 2010.) Available from http://hivdb.stanford.edu
23. Laboratory for Clinical and Evolutionary Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven. Rega algorithms. (Accessed 30 May 2010.) Available from http://www.rega.kuleuven.be/cev/index.php?id=30
24. Picchio G, De Meyer S, de Béthune MP. Response to 'key amprenavir resistance mutations counteract dramatic efficacy of DRV in highly experienced patients'. AIDS 2008; 22:165-167. (Pubitemid 350294899)
25. Guidelines from the Agence Nationale pour la Rechèrche sur le Sida. (Accessed 30 May 2010.) Available from www.hivfrenchresistance.org/2008/ Algo-2008.pdf
26. De Luca A, Cingolani A, Di Giambenedetto S, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 187:1934-1943. (Pubitemid 36724492)
27. De Luca A, Di Giambenedetto S, Marando F, et al. Improved interpretation and clinical validation of substitutions in HIV-1 protease predicting the virological response to DRV/RTV. Antivir Ther 2008; 13 Suppl 3:A104.
28. Zaccarelli M, Lorenzini P, Ceccherini-Silberstein F, et al. Historical resistance profile help to predict salvage failure. Antivir Ther 2009; 14:285-291.